AbbVie

What AbbVie does

AbbVie is a global research and development-driven biopharmaceutical company, headquartered in North Chicago, Illinois (USA) and publicly traded on the NYSE under ticker ABBV. The company was established in January 2013 as a spin-off of the pharmaceutical business from Abbott Laboratories and operates across five therapeutic areas: immunology, oncology, neuroscience, virology, and medical aesthetics. AbbVie's commercial portfolio includes major brands such as Humira (adalimumab), Skyrizi (risankizumab), Rinvoq (upadacitinib), Venclexta/Venclyxto (venetoclax), Epkinly (epcoritamab), Maviret (glecaprevir/pibrentasvir), Duodopa/Vialeb (Parkinson's therapies), Aquipta (atogepant), and the Allergan Aesthetics range (Botox Vista, Juviderm/SkinBiv). Underlying scientific platforms span monoclonal antibodies (IL-23/p19, TNFα, CD20), small molecules (JAK1, BCL-2, CGRP, D3), bispecific antibodies (DuoBody technology), antibody-drug conjugates, and gene therapy (ABBV-RGX-314). The company operates 9 global R&D facilities with 14,000+ scientists, runs 375 active clinical trials across 50+ countries, and has a pipeline of 90+ drug candidates including ~50 NMEs in development.

In Japan, AbbVie GK (アッヴィ合同会社) is a wholly-owned subsidiary established in January 2013, headquartered in Minato-ku, Tokyo. The Japanese operations employ 1,970 staff across 42 domestic locations and generated ~$1.274B in revenue in FY2025 (+14% YoY). AbbVie Japan has secured 22 regulatory approvals since 2020, including multiple world-first launches (Skyrizi for psoriasis in 2019, Humira for pyoderma gangrenosum in 2020, Vialeb for Parkinson's in 2023), and holds No.1 market share positions in IL-17/23 biologics and JAK inhibitor categories. The new 5-year plan 'Beyond the Best' (started March 2025) targets top 10 pharmaceutical sales ranking in Japan and doubling of sales by 2029. In August 2023, AbbVie completed a merger with Allergan Japan, integrating the medical aesthetics franchise under the AbbVie GK Allergan Aesthetics brand. The Japanese business is supported by an enterprise field sales motion through Medical Representatives with National Partner and Area Partner career tracks, and operates across all five global therapeutic areas with active participation in 100+ clinical trials in Japan.

Name

AbbVie

Legal name

アッヴィ合同会社 (AbbVie GK)

Website

https://abbvie.co.jp

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

251–500 employees

Short description

AbbVie is a global R&D-driven biopharmaceutical company operating across immunology, oncology, neuroscience, virology, and medical aesthetics, selling prescription medicines like Skyrizi, Rinvoq, Humira, Venclexta, Epkinly, and Botox in ~180 countries. Its Japanese subsidiary (AbbVie GK) employs 1,970 staff and serves Japanese patients and healthcare providers across 42 domestic locations.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Biopharmaceutical products
• Prescription medicines
• Immunology therapeutics
• Oncology therapeutics
• Medical aesthetics products

Headquarters

HQ city

North Chicago

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D

Revenue model

1. Prescription Pharmaceutical Products: AbbVie generates revenue primarily through the sale of prescription pharmaceutical products across five therapeutic areas: immunology, oncology, neuroscience, virology, and medical aesthetics. Major brands include Humira, Skyrizi, Rinvoq, Vraylar, Botox, and Imbruvica. Revenue is generated through direct sales to healthcare providers, hospitals, pharmacies, and distributors in approximately 180 countries.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Core offering

AbbVie is a global research-driven biopharmaceutical company that develops, manufactures, and sells prescription pharmaceutical products across five therapeutic areas: immunology (Humira, Skyrizi, Rinvoq), oncology (Venclexta, Epkinly), neuroscience (Duodopa, Aquipta), virology (Maviret), and medical aesthetics (Botox Vista, Juviderm). The company operates 9 R&D facilities with 14,000+ scientists, advancing 90+ drug candidates and approximately 50 new molecular entities targeting 75 disease areas.

Product overview

AbbVie is a global research and development biopharmaceutical company offering a portfolio of innovative medicines across five therapeutic areas: Immunology (including Skyrizi, Rinvoq, and Humira biologics), Oncology (including Epkinly and Venclexta), Neuroscience (including Aquipta for migraine and Vraylar for bipolar disorder), Virology (including Maviret for Hepatitis C), and Medical Aesthetics (Botox Vista and SkinBiv). The company operates primarily as a pharmaceutical products company rather than a software platform. Key products include biologic therapies (monoclonal antibodies like Skyrizi and Humira), small molecule drugs (JAK inhibitors like Rinvoq, BCL-2 inhibitors like Venclexta), and gene therapies in development. The portfolio addresses autoimmune diseases, blood cancers, neurological conditions, viral infections, and aesthetic medicine.

Differentiator

Problem solved

Functional benefit

Brands

• Allergan Aesthetics (アラガン・エステティックス): Aesthetic medicine and medical aesthetics portfolio including Botox, dermal fillers, and skin care products
• アラガン・エステティックス

Products and services

• Humira (adalimumab) Human anti-human TNFα monoclonal antibody biologic for rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, uveitis, intestinal Behcet's disease, generalized pustular psoriasis, pyoderma gangrenosum, and non-radiographic axial spondyloarthritis. Used by rheumatology, gastroenterology, and dermatology specialists.
• Skyrizi (risankizumab) Humanized anti-IL-23p19 monoclonal antibody for psoriasis, psoriatic arthritis, generalized pustular psoriasis, erythrodermic psoriasis, palmoplantar pustulosis, Crohn's disease, and ulcerative colitis. Used by dermatologists and gastroenterologists.
• Rinvoq (upadacitinib) Oral selective JAK1 inhibitor for rheumatoid arthritis, atopic dermatitis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, ulcerative colitis, Crohn's disease, and giant cell arteritis. Used by rheumatologists, dermatologists, and gastroenterologists.
• Epkinly (epcoritamab) Bispecific CD3xCD20 DuoBody antibody co-developed with Genmab for relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma. Used by hematologists and oncologists.
• Venclexta (venetoclax) Oral selective BCL-2 inhibitor for chronic lymphocytic leukemia, acute myeloid leukemia, and relapsed/refractory mantle cell lymphoma. Used by hematologists.
• Aquipta (atogepant) Oral CGRP receptor antagonist for migraine prophylaxis and acute migraine attack suppression in adults. Used by neurologists and headache specialists.
• Maviret (glecaprevir/pibrentasvir) Oral direct-acting antiviral combination for chronic hepatitis C virus infection across all major genotypes (GT1-6), with pediatric granule formulation for children aged 3+. Used by hepatologists and infectious disease specialists.
• Vialeb (foscarbidopa/foslevodopa) Continuous subcutaneous infusion therapy for advanced Parkinson's disease with wearing-off phenomenon, providing continuous dopaminergic stimulation. Used by neurologists and movement disorder specialists.
• Duodopa (levodopa/carbidopa intestinal gel) Enteral intestinal gel formulation for advanced Parkinson's disease with motor complications. Used by neurologists and movement disorder specialists.
• Botox Vista (onabotulinumtoxinA) Type A botulinum toxin product (Allergan Aesthetics brand) for glabellar lines, lateral canthal lines, and masseter hypertrophy in aesthetic medicine. Used by dermatologists, plastic surgeons, and aesthetic clinics.
• SkinBiv by Juviderm Vista Hyaluronic acid-based soft tissue injectable (Allergan Aesthetics brand) for skin quality improvement. Used by dermatologists and aesthetic practitioners.

Quantifiable outcome

• Top 10 pharmaceutical company in Japan by sales (target: 2029)
• +3 more outcomes

Named customers4 records

Segments6 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

13 partnerships are on record, tiered minor and core.

• BioLabsminorStrategic or Co-development Partner · 1 January 2026AbbVie and BioLabs entered a strategic partnership in April 2026 to support the AbbVie Japan Innovation Award program, fostering early-stage biotech innovation in Japan. The partnership aims to identify and support promising Japanese biotech companies.
• National Cancer Center Japan (NCC)minorStrategic or Co-development Partner · 1 January 2026AbbVie is a member of ENSEMBLExJ, a national government-backed initiative led by the National Cancer Center to support overseas biotech and emerging biopharma companies with clinical development, regulatory consultations, and market entry in Japan.
• GenmabcoreStrategic or Co-development Partner · 1 January 2020AbbVie and Genmab co-develop and co-commercialize epcoritamab (DuoBody-CD3xCD20), a bispecific antibody for B-cell malignancies. Genmab contributes its DuoBody technology platform; AbbVie leads global commercialization. EPKINLY has been approved in Japan (November 2023) for relapsed/refractory DLBCL and in the EU for DLBCL and FL.
• REGENXBIOcoreStrategic or Co-development PartnerAbbVie and REGENXBIO co-develop ABBV-RGX-314 (subranogene abeparvovec), a gene therapy candidate for neovascular age-related macular degeneration (wet AMD). AbbVie holds an exclusive license for development and commercialization globally.
• ArgenxcoreStrategic or Co-development PartnerAbbVie has partnered with Argenx on ABBV-151 (livmoniplimab), a GARP-TGF-β1 inhibiting antibody for cancer treatment. The partnership leverages Argenx's immunology platform for oncology applications.
• Gedeon RichterminorStrategic or Co-development PartnerAbbVie partnered with Gedeon Richter to develop ABBV-932, a selective dopamine D3 receptor modulator for bipolar disorder and generalized anxiety disorder. Richter contributes CNS drug development expertise.
• Hiroshima UniversityminorStrategic or Co-development PartnerAbbVie Japan and Hiroshima Prefecture signed a partnership agreement to promote hepatitis screening and treatment. The collaboration includes creating educational materials for healthcare providers to improve HCV testing rates and specialist referrals.
• Japan Dermatology SocietyminorStrategic or Co-development PartnerAbbVie co-funds the Japan Dermatology Society Inflammatory Skin Disease Research Grant (AbbVie Grant), established in 2017, providing ¥3 million annually to support research in inflammatory skin diseases.
• Japan Spondyloarthritis SocietyminorStrategic or Co-development PartnerAbbVie co-funds the Shichikawa-AbbVie Award with the Japan Spondyloarthritis Society, established in September 2017 to promote research in spondyloarthritis.
• Japan Society of Neurology and Parkinson's Disease (MDSJ)minorStrategic or Co-development PartnerAbbVie co-funds the MDSJ Overseas Dispatch Program with the Japanese Society of Neurology and Parkinson's Disease, established in 2022 to support young researchers in attending international conferences.
• Japan Heart (ジャパンハート)minorGTM or Marketing PartnerAbbVie partners with NPO Japan Heart to operate the AbbVie Kids Seminar program for children with pediatric cancer and their families, with employee volunteer participation.
• Stop Kansen Project (肝炎撲滅プロジェクト)minorGTM or Marketing PartnerAbbVie participates in the Stop Kansen Project, a cross-industry coalition aimed at eliminating hepatitis in Japan, alongside government and academic partners.
• Know Hepatitis Project (知って、肝炎プロジェクト)minorGTM or Marketing PartnerAbbVie participates in the national Know Hepatitis Project to raise awareness about hepatitis B and C screening and treatment in Japan.

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Amgen: Amgen is a direct peer focused on biologics with overlapping immunology (Enbrel, Otezla, Tezspire), oncology (Blincyto, Lumakras), and biosimilar franchises. Amgen's biologics manufacturing and pipeline depth make it one of the closest comparables for AbbVie's immunology and bispecific antibody strategy.
• Bristol-Myers Squibb: BMS is a direct peer in oncology (Revlimid, Pomalyst, Opdivo) and immunology (Zeposia, Sotyktu). BMS competes with AbbVie's hematology portfolio (Venclexta, Imbruvica) and increasingly in immunology with TYK2 and S1P modulators. Both companies have similar post-LOE transitions and pipeline renewal pressures.
• Johnson & Johnson (Innovative Medicine): J&J's Innovative Medicine segment is a direct peer with overlapping immunology (Stelara, Tremfya, Remicade), oncology (Darzalex, Imbruvica — co-marketed with AbbVie), and neuroscience franchises. Both companies operate at similar scale and target the same prescriber base of rheumatologists, dermatologists, and oncologists globally.
• Novartis: Novartis is a direct peer across neuroscience (Aimovig competes with Aquipta in migraine), oncology (Kisqali competes in hematology/oncology adjacencies), and immunology (Cosentyx in IL-17A competes with Skyrizi). Both companies pursue branded specialty care globally with similar payer access dynamics.
• Pfizer: Pfizer is a global research-based biopharmaceutical company with comparable scale (>$60B revenue), a similar mix of branded specialty pharmaceuticals across immunology, oncology, neuroscience, and vaccines, and direct overlap with AbbVie in JAK inhibitors and oncology. Pfizer competes head-to-head with Rinvoq via Cibinqo and Xeljanz and with Skyrizi via emerging IL-23 entrants.
• Sanofi: Sanofi is a direct peer in immunology (Dupixent competes with Rinvoq in atopic dermatitis and other Type 2 inflammatory indications), vaccines, and rare disease. Dupixent's growth trajectory in atopic dermatitis is a meaningful head-to-head competitive overlap with AbbVie's Rinvoq.
• Merck & Co. Merck is a direct peer in oncology (Keytruda dominates AbbVie's oncology ambitions) and is expanding into immunology and neuroscience. Both companies compete for the same specialty-care physician audience and operate large global R&D organizations targeting similar therapeutic areas.
• Eli Lilly: Lilly is a direct peer in immunology (Taltz, Olumiant, Ebglyss), oncology, and neuroscience, with a comparable R&D-driven innovation model. Lilly's IL-23 (Taltz) and emerging IL-13 (lebrikizumab, Ebglyss) franchises compete directly with Skyrizi and Rinvoq for the same patients.
• Roche: Roche is a direct peer in oncology (hem-onc and solid tumor), neuroscience (Ocrevus, Evrysdi), and immunology/ophthalmology. Roche's biopharma scale, R&D breadth, and biologics manufacturing platform closely mirror AbbVie's structural profile.

Regional players

• Takeda Pharmaceutical: Takeda is a Japan-headquartered global biopharmaceutical peer operating in similar therapeutic areas (rare disease, oncology, neuroscience, GI). While Takeda is much more focused on rare disease and plasma-derived therapies post-Shire, it competes with AbbVie Japan for the same top-tier Japanese sales ranking, regulatory attention, and KOL relationships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/abbvie
• YouTubeyoutube.com/c/AbbVieJapan
• Facebookfacebook.com/AbbVieJapan
• LinkedInlinkedin.com/company/ssp-co.-ltd.
• Instagraminstagram.com/abbvie

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AbbVie